E pithelial monolayer integrity is, to a significant extent, maintained through cell-cell adhesion, the cytoskeleton and basement membrane interaction [1] [2] [3] . Cell adhesion proteins and the cytoskeleton are intimately associated, with the E-cadherin-catenin complex and filamentous actin (F-actin) being prime examples. E-cadherin participates in cell adhesion and contact inhibition as part of a large complex composed of catenins and additional proteins (such as α -, β -and p120-catenin, vinculin, α -actinin and eplin) that is stabilized by interactions with F-actin [2] [3] [4] [5] . F-actin polymerization, which involves the addition of ATP-globular actin (G-actin) at the barbed (or + ) end of filaments, is controlled by capping proteins (CPs) and CP regulators 6 . CPs directly bind and block the barbed end of filaments or ATP-G-actin, resulting in the inhibition of actin assembly. Several CP regulators control CPs. For example, formins and Ena/VASP compete with CPs for actin binding 7, 8 . Alternatively, V-1 and phospholipids bind to CPs and prevent interactions between CPs and actin 9, 10 . Given that F-actin stabilizes the E-cadherin-catenin complex for the maintenance of epithelial cell integrity, we hypothesized that reduced epithelial cell integrity through the deregulation of the cytoskeleton and the E-cadherin-catenin complex contributes to tumorigenesis. Our unbiased and comprehensive approaches identified cancer-related regulator of actin dynamics (CRAD; KIAA1211) as a tumour suppressor in colorectal cancer (CRC).
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CRAD is markedly mutated in small cell lung cancer patient samples, ranked as the third most frequently mutated gene after TP53 and RB1
11
. Here, our comprehensive approaches reveal that CRAD inactivation initiates mucinous intestinal tumorigenesis by disrupting epithelial cell integrity.
CRAD inactivation in CRC
To identify potential tumour-suppressor genes that are specifically inactivated in CRC, we selected genes whose expression is significantly downregulated in CRC. Analysis of Oncomine datasets showed that the transcriptional level of CRAD was notably downregulated in CRC samples (Fig. 1a) . Similarly, analysis of Gene Expression Omnibus (GEO) datasets indicated a significant downregulation of CRAD mRNA in CRC compared to the adjacent normal samples (Fig. 1b) . Immunohistochemistry (IHC) of tissue microarrays (TMAs) also showed decreased CRAD in CRC ( Fig. 1c and Supplementary Table 1) . Furthermore, CRC cells exhibited reduced CRAD mRNA expression ( Fig. 1d ) and protein levels ( Supplementary Fig 1) . Interestingly, transcriptional downregulation of CRAD was observed in CRC cell lines without CRAD genetic mutations (Fig. 1d ) but was restored with the inhibition of methyltransferase ( Supplementary Fig. 1c ). These results suggest that CRAD is inactivated by genetic mutation or transcriptional downregulation in CRC.
Positive regulation of actin polymerization by CRAD
Given the mutation or downregulation of CRAD in CRC, we hypothesized that CRAD is a tumour suppressor in CRC. To test this, we examined whether CRAD inactivation is involved in cell transformation-related cell morphological change 12 , as reflected in the respective cell morphologies and actin distributions of IECs compared to CRC cell lines ( Supplementary Fig. 2a,b) . We found that CRAD depletion ( Supplementary Fig. 2c,d ) induced IEC shrinkage ( Supplementary Fig. 2e ,f), which was indicated by reduced cell areas and decreased phalloidin staining, a marker for F-actin ( Supplementary Fig. 2g ). Conversely, CRAD ectopic expression increased the cell area of CRC cells, with an elevated actin cytoskeleton ( Supplementary Fig. 2h-k) . These results suggest that CRAD positively regulates the actin polymerization.
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CRAD as an inhibitor of CPs
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capping proteins CAPZA1, CAPZB and CAPZA2 exhibited high scores with regards to peptide numbers. Co-immunoprecipitation (co-IP) from cell lysates and pull-down assays of purified proteins validated the endogenous and direct interaction between CRAD and the CPs ( Fig. 2b and Supplementary Fig. 2l ). Thus, we hypothesized that CRAD enhances F-actin polymerization by inhibiting CPs (Fig. 2c) . We examined whether CRAD interferes with the binding of CPs to actin. Co-immunoprecipitation assays showed that ectopic CRAD reduced the interaction between CPs and actin ( Fig. 2d,e) . F-actin controls the cytoskeletal dynamics and stretched cell morphologies ( Supplementary Fig. 2e -k) [13] [14] [15] . For F-actin assembly, monomeric G-actin undergoes polymerization at the barbed end through a conformational change, represented by the high ratio of F-actin to G-actin. Fractionation of F-/G-actin indicated a decrease in F-actin levels in CRAD-depleted IECs (Fig. 2f and Supplementary  Fig. 2m ). Conversely, CRAD ectopic expression increased F-actin in CRC cells ( Supplementary Fig. 2n,o) , which is consistent with the phalloidin staining. Having determined that CPs directly bind to the barbed end of F-actin and inhibit F-actin polymerization 6 , we next investigated whether CRAD sequesters CPs from F-actin and increases the uncapped barbed ends of F-actin. Visualization of the uncapped barbed ends 16 showed that the ectopic expression of CRAD led to an increase in uncapped barbed ends (Fig. 2g) . In addition, highly expressed CRAD increased the uncapped barbed ends in the Latrunculin B (Lat B; an inhibitor of monomeric G-actin)-treated condition but not in the Cytochalasin D (Cyto D; a blocker of barbed end)-treated condition (Fig. 2g) . These results suggest that CRAD-upregulated actin polymerization is mainly due to the increase of the extendable barbed ends by inhibiting CPs, independently of the increase of monomeric G-actin. Direct CP regulators, including CARMILs, FAM21 and CD2AP, harbour a CP interaction (CPI) motif 6 . Interestingly, CRAD also contains two potential CPI motifs at amino acid residues 329 and 417 (Fig. 2h ). To determine whether these predicted CPI motifs in CRAD are required for CP inhibition, we constructed CRAD mutants (M1-M4 and Δ CPI; Fig.  2i ,j). Co-immunoprecipitation showed that, unlike full-length and M2-M4 mutants, M1 and Δ CPI mutants (lacking CPI motifs) did not bind to CPs (Fig. 2k ) and failed to inhibit the interaction of CPs with actin ( Fig. 2l) . In vitro protein binding assays using the purified proteins of actin, CPs and CRAD-M2 ( Supplementary Fig. 2p ) also showed that CRAD inhibited actin-CP binding ( Fig. 2m and Supplementary Fig.2q ). Moreover, in CRC cells, M1 and Δ CPI mutants failed to induce a stretched cell morphology ( Fig. 2n ) and F-actin polymerization (Fig. 2o ) unlike other mutants (M2-M4; Fig. 2n ,o). These data suggest that CRAD downregulates the interaction between CPs and the barbed ends via the CPI motifs in CRAD, which increases F-actin polymerization ( Supplementary Fig. 3 ).
CRAD loss-activated Wnt signalling by disrupted CCA complex
We next sought to determine CRAD-modulated actin cytoskeletons are associated with intestinal tumorigenesis. Owing to the deregulation of various developmental pathways in CRC, we examined the effects of CRAD on Wnt, Hedgehog, BMP, Notch and Hippo signalling. Interestingly, CRAD overexpression downregulated Wnt/β -catenin target genes (AXIN2 and CD44; Fig. 3a) . Conversely, in IECs, CRAD depletion augmented Wnt/β -catenin target-gene expression (Fig. 3b ). In addition, CRAD expression is mutually exclusive to the expression of AXIN2 in CRC ( Supplementary  Fig. 4a ). The level of nuclear β -catenin in IECs and CRC cell lines was consistently inversely correlated with the expression of CRAD (Fig. S4b) . These results imply that CRAD might be negatively associated with Wnt/β -catenin signalling. Indeed, CRAD depletion increased β -catenin reporter activity, AXIN2 expression and the level of active β -catenin in IECs (Fig. 3c-e) . Importantly, the treatment of cells with iCRT14, an inhibitor of β -catenin-TCF binding, suppressed CRAD depletion-induced β -catenin reporter activation (Fig. 3f) . Also, Engrailed-LEF1 (Eng-LEF1), a dominant-negative mutant blocking β -catenin-mediated gene activation 17 , suppressed AXIN2 upregulation in CRAD-depleted IECs (Fig. 3g) . These results indicate that CRAD knockdown-induced upregulation of the β -catenin reporter and target genes is due to β -catenin-mediated transcriptional activation.
To complement this, we examined the effects of CRAD ectopic expression on Wnt/β -catenin signalling in CRC cells. CRAD expression suppressed β -catenin reporter activity, AXIN2 and active β -catenin ( Fig. 3h-j) . Moreover, the M1 and Δ CPI constructs failed to downregulate AXIN2 (Fig. 3k) , which suggests that the CPI motifs in CRAD are required for the suppression of β -catenin target-gene activation.
Catenin proteins connect E-cadherin to the actin cytoskeleton, which contributes to the maintenance of epithelial cell integrity through cell-cell adhesion 4, 5, 18, 19 and downregulates the nuclear translocation of catenins 20 . Given the role of CRAD in modulating the actin cytoskeleton ( Fig. 2) , we investigated whether CRAD has an impact on the interaction between catenins and E-cadherin. In IECs, CRAD knockdown increased the levels of β -catenin and α -catenin both in the cytosol and the nucleus ( Fig. 3l and Supplementary Fig. 4c ). Conversely, CRAD expression decreased nuclear β -catenin in HCT116 CRC cells ( Fig. 3m and Supplementary  Fig. 4d ) and co-IP assays showed that CRAD knockdown reduced the interaction between E-cadherin and catenin proteins ( Fig. 3n and Supplementary Fig. 4e ). In CRC cells, however, CRAD overexpression induced the binding of catenin proteins with E-cadherin ( Fig. 3o and Supplementary Fig. 4f ). Super Resolution microscopic analyses also showed that CRAD-expressing HCT116 cells displayed increased β -catenin associated with E-cadherin in cell-cell adhesion ( Fig. 3p and Supplementary Fig. 4g ). Given that the actin cytoskeletal dynamics modulate E-cadherin-mediated cell adhesion 5, 18, 21 , we investigated whether CRAD-modulation of the actin cytoskeleton affects E-cadherin-catenin binding. Duolink (Fig. 3q ) and co-IP assays showed that the ectopic expression of the full-length and M2-M4 mutants stabilized the E-cadherin-catenin complex, whereas M1 and Δ CPI mutants did not (Fig. 3r,s) . We also verified β -catenin transcriptional activity under conditions of actin-cytoskeletal inhibition versus stabilization. Actin polymerization inhibitors (Lat B and Cyto D) increased the transcriptional activity of β -catenin, whereas an F-actin stabilizer (Jasplakinolide) reduced it ( Supplementary  Fig. 4h,i) . These results suggest that under normal conditions, CRAD enhances the actin polymerization through CP inhibition, which stabilizes the cadherin-catenin-actin (CCA) complex. Conversely, after CRAD inactivation, a diminished actin cytoskeleton destabilizes the CCA complex. This releases β -catenin from the cadherin, followed by nuclear translocation of β -catenin and activation of Wnt/β -catenin target genes ( Supplementary Fig. 4j ).
Inhibition of CRC cell proliferation by CRAD
Having observed the inactivation of CRAD in CRC (see Fig. 1 ) and CRAD inactivation-induced Wnt/β -catenin signalling activation, we next determined the effects of CRAD on IEC and CRC cell proliferation. Given the high expression of CRAD in IECs, we depleted endogenous CRAD in IECs using short hairpin RNA (shRNA). The knockdown of CRAD increased IEC proliferation (Fig. 4a) , which was reversed by iCRT14 ( Fig. 4b and Supplementary Fig.  5a ,b) or Eng-LEF1 ( Fig. 4c and Supplementary Fig. 5c-e) . These data indicate that CRAD depletion-induced IEC hyperproliferation is mediated by β -catenin target-gene activation. Conversely, CRAD overexpression inhibited CRC cell proliferation ( Fig. 4d and Supplementary Fig. 5f-h ), which was rescued by β -catenin ( Fig. 4e and Supplementary Fig. 5i-o) . These results suggest that CRAD-induced CRC cell growth inhibition is mainly due to the suppression of β -catenin signalling. Furthermore, unlike the CTGF  CYR61  HES1  HEY1  GLI1  PTCH1  PTHLH  RUNX2  AXIN2  CD44   UD  mRNA fold induction  (qRT-PCR) shCtrl shCRAD 
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full-length and M2-M4 mutants, the Δ CPI and M1 constructs did not inhibit CRC cell proliferation (Fig. 4f,g and Supplementary  Fig. 5p,q) . Importantly, CRAD depletion-induced IEC hyperproliferation was reverted by the expression of the full-length mutant, but not by expression of the Δ CPI mutant (Fig. 4h) . Similarly, β -catenin reporter activity was downregulated by the full-length and M2-M4 mutants but not by the Δ CPI or M1 mutants (Fig. 4i,j) . These results suggest that the CPI motifs of CRAD are required to inhibit CRC cell proliferation. Furthermore, xenograft transplantation assays showed that, compared to HCT116, HCT116-CRAD injected mice exhibited reduced tumour development (Fig. 4k,l) , with notably decreased The cell proliferation of HCT116 and HCT15 cells (Vec (control) and CRAD-expressing) was analysed. e, CRAD-induced CRC cell growth inhibition is rescued by β -catenin. HCT116 and HCT15 cells were transfected with CRAD or β -catenin plasmids and cell proliferation was analysed. f-h, CRC cell growth inhibition by CPI motif-containing CRAD mutants. The cell proliferation of CRAD (full-length, Δ CPI and M1-M4)-transfected CRC cells, HCT116 (f) and SW620 cells (g), was analysed. h, CCD-841CoN cells were transfected with each plasmid and the cell proliferation was analysed. i,j, Suppression of β -catenin reporter by CPI motif-containing CRAD mutants. HCT116 (i) and SW620 (j) cells transfected with CRAD full-length or mutant constructs were analysed for luciferase activity. k-o, Inhibition of ex vivo tumour development by CRAD. HCT116 control and HCT116-CRAD cells were subcutaneously injected into the left (green arrows) and right (red arrows) mouse flank, respectively (k, lower panel indicates isolated tumours from each mouse), and analysed for tumour weight (l; n = 10 mice) and IHC (m-o) using Ki67 (m), phalloidin (n) and CD44 (o). White boxes indicate regions magnified in dashed boxes. The experiments in k and l were performed once. Data in a-j and o are from three independent experiments. Scale bars, 20 μ m; error bars, mean ± s.d.; NS, not significant (P > 0.05); two-sided unpaired t-test.
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Intestinal adenoma development due to CRAD knockout
To address the in vivo consequence of CRAD gene inactivation in CRC, we established a CRAD knockout (KO) mouse model ( Fig. 5a and Supplementary Fig. 6a-d) . Importantly, CRAD KO mice displayed adenoma development in the small intestine (Fig. 5b,c) in an age-dependent manner (Fig. 5d) . In addition, we found that CRAD KO mice showed decreased expression of Wnt/β -catenin target genes without the alteration of other signallings ( Supplementary  Fig. 6e ). Intriguingly, CRAD KO mice also developed pulmonary lesions resembling early small cell lung cancer and solid-pseudopapillary neoplasm of the pancreas ( Supplementary Fig. 6f,g ). These results are supported by previous studies that show high mutation rates of CRAD in small cell lung cancer 11 and the constitutively active mutation of β -catenin in solid-pseudopapillary neoplasm of the pancreas 22 . Interestingly, mucin deposition in CRAD KO-induced intestinal adenoma was observed by hematoxylin and eosin (H&E) staining and periodic acid-Schiff (PAS) staining (Fig. 5e,f) . Moreover, CRAD KO tumours displayed a heterogeneous loss of epithelial cell integrity (H&E and Cytokeratin 19 Fig. 6h) . Loss of epithelial cell integrity is known to induce mucosal secretion and intestinal inflammation 23 . It should be noted that CRAD KO mice displayed a slight increase in intestinal inflammation 
Articles
NATuRE CEll BIOlOgy (Fig. S6i,j) . We also observed cell hyperproliferation in CRAD KO mice, indicated by elevated numbers of Ki67-and phosphoHistone H3-positive cells (Fig. 5h and Supplementary Fig. 6k -n) without notable differences in cell death (Supplementary Fig.  6o ). Furthermore, IHC results for lysozyme (Paneth cells) and chromogranin A (neuroendocrine cells) indicated an increase in Paneth cells and a decrease in neuroendocrine cells in the CRAD KO intestine (Fig. 5i and Supplementary Fig. 6p ), which might be because canonical Wnt signalling induces Paneth cell differentiation 24 . Given that CRAD depletion activates Wnt/β -catenin signalling by disrupting the CCA complex (see Fig. 3 ), we also examined cell-cell adhesion. CRAD KO mice showed the disorganized localization of E-cadherin and villin ( Fig. 5j and Supplementary  Fig. 6q ). In addition, β -catenin and its target genes were upregulated in CRAD KO mice (Fig. 5k,l and Supplementary Fig. 6r ) and CRAD KO-induced intestinal tumours exhibited disorganized and decreased levels of F-actin (Fig. 5m) . Moreover, compared to wild type (WT), intestinal extracts from the CRAD KO mice showed a delayed rate in actin polymerization (Fig. 5n) . These results strongly suggest that CRAD KO per se is sufficient to initiate intestinal tumorigenesis with the loss of epithelial cell integrity and the aberrant activation of Wnt/β -catenin signalling.
Accelerated intestinal tumorigenesis by CRAD Ko
Given that CRAD gene mutations are often heterozygous in CRC patients ( Supplementary Fig. 7a ), we investigated whether genetic ablation of one allele of CRAD is associated with intestinal tumorigenesis. Compared to the APC MIN strain, APC
MIN
:CRAD +/− mice exhibited an increase in tumour numbers in the small intestine (Fig. 6a-c) without a change in β -catenin or cell proliferation (Fig. 6d-f) . Furthermore, unlike adenomas from APC MIN , tumours of APC MIN :CRAD +/− mice displayed a loss of both F-actin (Fig. 6g) and epithelial cell properties (Fig. 6h) , as observed in CRAD KO mice (see Fig. 5g,m) . Whereas APC MIN mice develop tumours mainly in the small intestine but not in the colorectum 25 , APC MIN 
:CRAD
+/− compound mice displayed severely invasive and mucinous adenomas in the colon (Fig. 6i-k) . Intriguingly, colonic tumours of APC MIN :CRAD +/− mice showed a marked increase in mucin accumulation (Fig. 6l) , similar to human mucinous adenocarcinoma (MAC) 26 . Colonic adenomas from APC MIN :CRAD +/− mice also exhibited significant upregulation of β -catenin (Fig. 6m) , cyclin D1 ( Fig. 6n and Supplementary Fig. 7b ,c) and cell hyperproliferation ( Fig. 6o and Supplementary Fig. 7d,e) . Consistent with tumours in the small intestine, the heterogeneous loss of both F-actin and CK19 was also observed in colonic tumours of APC MIN :CRAD +/− mice (Fig. 6p,q) . Moreover, we observed the invasive adenoma development in APC MIN :CRAD +/− mice, represented by the disruption of the basal membrane (Supplementary Fig. 7f ). It should be noted that both APC MIN and APC
MIN
:CRAD +/− mice did not express mesenchymal markers (Supplementary Fig. 7g ), which implies that epithelialmesenchymal transition might not be involved in invasive tumour development in APC MIN :CRAD +/− mice. These results suggest that, in conjunction with APC inactivation, the deletion of a CRAD allele leads to intestinal tumorigenesis in both the small and large intestine, which reveals a pathologic outcome of CRAD heterozygous mutation during intestinal tumorigenesis.
Mucinous intestinal tumorigenesis by CRAD Ko
We next examined the mucinous tumour phenotype driven by CRAD KO. Transformation or early tumour lesions can be assessed by the development of cystic spheroid organoids instead of the normal crypt organoids 27 . Interestingly, CRAD KO developed the cystic spheroid, as shown in APC MIN organoids (Fig. 7a) . 
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CRAD KO cystic organoids exhibited increased cell proliferation ( Fig. 7b and Supplementary Fig. 8a ), stabilized β -catenin ( Fig. 7c and Supplementary Fig. 8b ), upregulated β -catenin target genes ( Fig. 7d-f) , disrupted actin cytoskeleton (Fig. 7g,h ), abnormality of epithelial cell integrity (Fig. 7i) , disorganized cell adhesion (Fig. 7j) and decreased IEC differentiation (Fig. 7k,l) . CRAD KO cystic organoids also displayed increased mucin expression (Fig. 8a,b) , as shown in CRAD KO tumours (see Fig. 5e,f) , which indicates that CRAD KO upregulates mucin expression in a cellautonomous manner. Goblet cells secrete various mucins and the number of goblet cells is elevated in MAC 28, 29 . Intriguingly, the nontumour and tumour regions of CRAD KO exhibited an increase in mucin expression (Fig. 8c and Supplementary Fig. 8c ) and goblet cell numbers (Supplementary Fig. 8d ). The marked upregulation of mMUC in CRAD KO tumours, but not in APC MIN tumours, was confirmed through qRT-PCR ( Fig. 8c and Supplementary Fig. 8e ). Despite the implication of the Wnt-Notch signalling axis in goblet cell differentiation 30 , only Wnt signalling target genes were upregulated by CRAD KO (Supplementary Fig. 6e ). MAC is characterized by amplification of the Topoisomerase-1 (TOP-1) allele 31 . We found that the CRAD KO tumours exhibited an increase in both TOP-1 mRNA and genomic DNA levels, whereas APC MIN tumours did not (Fig. 8e,f) . CRAD KO tumours and cystic spheroids also showed TOP-1 upregulation (Fig. 8g and Supplementary Fig. 8f ). Note that TOP-1 upregulation (2 months; Supplementary Fig. 8g ) precedes mucin deposition (4 months; Fig. 8c,d and Supplementary  Fig. 8c ). Furthermore, IHC of MAC TMA demonstrated downregulated CRAD expression in MAC patient samples (Fig. 8h-j) . Oncomine datasets also indicated that CRAD expression is mutually exclusive to the expression of MUC5B and MUC5AC in MAC (Supplementary Fig. 8h ). These data suggest that the loss or downregulation of CRAD is associated with the development of MAC. Together, our results strongly suggest that the deletion of CRAD leads to the mucinous intestinal tumorigenesis.
Discussion
The mutation of APC in CRC causes aberrant Wnt/β -catenin signal activation. However, the β -catenin protein exhibits heterogeneous nuclear localization in the presence of homogeneous mutations in APC 32, 33 . This 'β -catenin paradox' model [32] [33] [34] [35] suggests that further 
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NATuRE CEll BIOlOgy activation of APC mutation-driven Wnt signalling contributes to intestinal tumorigenesis. In epithelial cells, APC competes with E-cadherin for β -catenin binding 36 , suggesting that β -catenin might also be partially sequestered by E-cadherin in the APC-mutated condition. Thus, it is likely that E-cadherin-mediated redistribution of β -catenin might be an additional layer limiting Wnt signalling in normal tissues.
Our study indicates that the interaction between the E-cadherincatenin complex and the actin cytoskeleton might be a key factor suppressing tumorigenesis. Similarly, during embryogenesis, cadherin antagonizes β -catenin activity 37 . Although E-cadherin and APC might also be potential candidate regulators for the CCA complex in tumorigenesis, the E-cadherin mutation rate is meagre in CRC 38 and the function of APC is inhibited by CPs
39
. Therefore, it is plausible that the defects in other key regulators of the CCA complex might be implicated in CRC. Our findings that CRAD ablationinduced F-actin depolymerization leads to intestinal tumorigenesis strongly suggest that CRAD-modulated actin cytoskeletal dynamics and CCA complex stabilization play a crucial tumour suppressive role in the intestinal epithelium.
A limitation of the APC MIN mouse model is that the development of intestinal adenomas mainly occurs in the small intestine and infrequently in the colorectum, unlike human CRC 25 . CRAD KO mice develop tumours in both the small and large intestine (Fig. 6 ), which recapitulates human CRC pathology. Moreover, APC MIN 
:CRAD
+/− mice display micro-invasion without epithelialmesenchymal transition (EMT) (Supplementary Figs 7f,g ), implying the potential roles of CRAD inactivation in CRC metastasis.
Mucinous colorectal carcinoma (10-15% of human CRC) is highly metastatic and therapeutically resistant 31 . However, the molecular mechanism of MAC development remains elusive. Tumours developed in CRAD KO mice display excessive mucin deposition (Figs. 5e,f, 6j,l) with TOP-1 upregulation (Fig. 8e,f) , mimicking human MAC. This is further supported by the downregulation of CRAD in human MAC (Fig. 8h-j) . Note that APC MIN mice do not develop mucinous adenoma, which implies that CRAD loss-induced MAC development process might include distinct pathologic events in addition to Wnt/β -catenin hyperactivation. In normal intestine, mucin secreted by goblet cells is primarily involved in innate host defence. However, abnormally elevated secretion of mucin contributes to CRC progression 40 . Thus, CRAD inactivation might also contribute to tumorigenesis via high mucin secretion, beyond Wnt signalling. It is noteworthy that CRAD KO cystic organoids display mucin upregulation in a cell-autonomous manner (Fig. 8a,b) , excluding the potential involvement of immunocytes in mucin expression. Given that there is no precedent MAC mouse model, our CRAD KO mice may be highly beneficial to studies of human MAC aetiology.
Together, the results of our study reveal that CRAD is a tumour suppressor and indispensable for the maintenance of epithelial cell integrity through the modulation of the cytoskeleton and thereby the CCA complex.
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